menu
    • menu
    [{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Cediprof"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"RIVOPHARM SA","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lannett Company, Inc. \/ Rivopharm SA","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Rivopharm SA"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Lannett Company, Inc. \/ Respirent Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Respirent Pharmaceuticals"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation powder","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Respirent Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tiotropium Bromide","moa":"Muscarinic M3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Lannett Company, Inc. \/ Lannett","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Lannett"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Verapamil Hydrochloride","moa":"Calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Lannett Company, Inc. \/ Lannett Company","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Lannett Company"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"HEC Group","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ HEC Group","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ HEC Group"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cocaine Hydrochloride","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Lannett Company, Inc.

    Menu

    Lannett Company, Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Receives Fda Approval To Manufacture Numbrino® At Seymour Plant

                            Details : Numbrino™ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.

                            Brand Name : Numbrino

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 21, 2022

                            Lead Product(s) : Cocaine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : HEC Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine

                            Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...

                            Brand Name : Glaricon

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 31, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : HEC Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Ver...

                            Details : Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.

                            Brand Name : Verelan PM

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : Verapamil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Societal CDMO

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine

                            Details : The first study, which the FDA reviewed, suggested that the HEC insulin glargine product would be biosimilar to US-approved Lantus® (the reference biologic) in terms of meeting the study's pharmacokinetics (PK) and pharmacodynamics (PD) endpoints.

                            Brand Name : HEC-Glargine

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 29, 2022

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiotropium Bromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Recipient : Respirent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            LANNETT Expands Respiratory Pipeline, Signs Exclusive Commercialization

                            Details : Lannett Company has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 29, 2021

                            Lead Product(s) : Tiotropium Bromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Recipient : Respirent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Submits ANDA For Generic ADVAIR DISKUS®

                            Details : Respirent Pharmaceuticals has summited an Abbreviated New Drug Application for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. FDA. The product is the generic equivalent of ADVAIR DISKUS of Glax...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2021

                            Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Respirent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lannett Signs Agreement with Respirent Pharmaceuticals for Exclusive Distributor Of Generic Flovent® Diskus®

                            Details : Lannett announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals.

                            Brand Name : Flovent Diskus

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 17, 2020

                            Lead Product(s) : Fluticasone Propionate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Respirent Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mexiletine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : RIVOPHARM SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lannett Launches Mexiletine HCl Capsules

                            Details : Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 23, 2020

                            Lead Product(s) : Mexiletine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : RIVOPHARM SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levothyroxine Sodium

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Cediprof

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lannett and Cediprof Announce Exclusive Distribution Agreement for An Approved Levothyroxine

                            Details : The companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett to Commence Marketing on August 3, 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : Levothyroxine Sodium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Cediprof

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Lannett Company, Inc.

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

                            Details : At the Biosimilar Biological Product Development Type II meeting the FDA provided positive feedback on the clinical and Chemistry, Manufacturing and Controls advancement of company's biosimilar insulin glargine that was consistent with our expectations.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 11, 2020

                            Lead Product(s) : Insulin Glargine

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth